Filter News
Area of Research
- (-) Nuclear Science and Technology (4)
- Biological Systems (1)
- Biology and Environment (20)
- Clean Energy (72)
- Computational Biology (2)
- Computational Engineering (1)
- Fusion and Fission (4)
- Isotopes (6)
- Materials (49)
- Materials for Computing (7)
- National Security (5)
- Neutron Science (25)
- Quantum information Science (1)
- Supercomputing (30)
- Transportation Systems (2)
News Topics
- (-) Biomedical (2)
- (-) Physics (2)
- 3-D Printing/Advanced Manufacturing (4)
- Advanced Reactors (11)
- Bioenergy (1)
- Computer Science (2)
- Coronavirus (1)
- Cybersecurity (1)
- Decarbonization (1)
- Environment (1)
- Fusion (8)
- Isotopes (5)
- Materials Science (3)
- Molten Salt (4)
- Neutron Science (5)
- Nuclear Energy (36)
- Space Exploration (5)
- Sustainable Energy (1)
- Transformational Challenge Reactor (3)
Media Contacts
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
As a teenager, Kat Royston had a lot of questions. Then an advanced-placement class in physics convinced her all the answers were out there.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
After more than a year of operation at the Department of Energy’s (DOE’s) Oak Ridge National Laboratory (ORNL), the COHERENT experiment, using the world’s smallest neutrino detector, has found a big fingerprint of the elusive, electrically neutral particles that interact only weakly with matter.